Brief: Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)
05/12/2024 13:11
Dec 5 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* RYVU THERAPEUTICS ANNOUNCES DOSING OF THE FIRST PATIENT IN
THE
POTAMI-61 PHASE II STUDY OF RVU120 FOR THE TREATMENT OF PATIENTS
WITH MYELOFIBROSIS (MF)
Source text: ID:nPnbHGpJza
Further company coverage: RVU.WA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys